Furthermore, due to their vascular effects, both DPP4 and ACE2/Ang II axis arise as potential therapeutic targets to ARDS and CV complications in COVID-19 that might be pharmacologically scoped, as it will be detailed below. This evidence concerns the gene DPP4 and COVID-19.